keyword
https://read.qxmd.com/read/38544837/emerging-role-of-m6a-modification-in-ovarian-cancer-progression-drug-resistance-and-therapeutic-prospects
#1
REVIEW
Shahil Alam, Pankaj Kumar Giri
Ovarian Cancer (OC) ranks as a prominent contributor to mortality among female reproductive system associated cancers, particularly the prevalent subtype epithelial Ovarian Cancer (EOC). Despite advancements in treatment modalities, the prognosis for OC patients remains grim due to limitation of current therapeutic methodology such as high cytotoxicity of chemotherapeutic agents and tumor relapse making existing chemotherapy ineffective. Recognizing the limitations of a broad-spectrum approach to treating OC, a shift toward targeted therapies aligning with unique molecular features is imperative...
2024: Frontiers in Oncology
https://read.qxmd.com/read/38543342/anticancer-potential-of-antimicrobial-peptides-focus-on-buforins
#2
REVIEW
Ana Maria Tolos Vasii, Cristian Moisa, Mihaela Dochia, Carmen Popa, Lucian Copolovici, Dana Maria Copolovici
In seeking alternative cancer treatments, antimicrobial peptides (AMPs), sourced from various life forms, emerge as promising contenders. These endogenous peptides, also known as host defense peptides (HDPs), play crucial roles in immune defenses against infections and exhibit potential in combating cancers. With their diverse defensive functions, plant-derived AMPs, such as thionins and defensins, offer a rich repertoire of antimicrobial properties. Insects, amphibians, and animals contribute unique AMPs like cecropins, temporins, and cathelicidins, showcasing broad-spectrum activities against bacteria, fungi, and viruses...
March 7, 2024: Polymers
https://read.qxmd.com/read/38540217/impact-of-obesity-and-lysosomal-dysfunction-on-chemoresistance-in-ovarian-cancer
#3
REVIEW
Boyun Kim, Jewon Jung
Obesity is recognized as a significant risk factor for ovarian cancer, with accumulating evidence highlighting its impact on disease progression and chemoresistance. This review synthesizes current research elucidating the link between obesity-induced lysosomal dysfunction and ovarian cancer chemoresistance. Epidemiological studies consistently demonstrate a positive correlation between body mass index (BMI) and ovarian cancer risk, attributed in part to the predilection of epithelial ovarian cancer cells for adipose tissue, particularly the omentum...
March 7, 2024: Biomedicines
https://read.qxmd.com/read/38539161/drug-resistance-in-ovarian-cancer-from-mechanism-to-clinical-trial
#4
REVIEW
Ling Wang, Xin Wang, Xueping Zhu, Lin Zhong, Qingxiu Jiang, Ya Wang, Qin Tang, Qiaoling Li, Cong Zhang, Haixia Wang, Dongling Zou
Ovarian cancer is the leading cause of gynecological cancer-related death. Drug resistance is the bottleneck in ovarian cancer treatment. The increasing use of novel drugs in clinical practice poses challenges for the treatment of drug-resistant ovarian cancer. Continuing to classify drug resistance according to drug type without understanding the underlying mechanisms is unsuitable for current clinical practice. We reviewed the literature regarding various drug resistance mechanisms in ovarian cancer and found that the main resistance mechanisms are as follows: abnormalities in transmembrane transport, alterations in DNA damage repair, dysregulation of cancer-associated signaling pathways, and epigenetic modifications...
March 28, 2024: Molecular Cancer
https://read.qxmd.com/read/38534790/the-role-of-urothelial-cancer-associated-1-in-gynecological-cancers
#5
REVIEW
Eleni Nousiopoulou, Kleio Vrettou, Christos Damaskos, Nikolaos Garmpis, Anna Garmpi, Panagiotis Tsikouras, Nikolaos Nikolettos, Konstantinos Nikolettos, Iason Psilopatis
Gynecological cancers (GC) represent some of the most frequently diagnosed malignancies in women worldwide. Long-non-coding RNAs (lncRNAs) are regulatory RNAs increasingly being recognized for their role in tumor progression and metastasis in various cancers. Urothelial cancer-associated 1 (UCA1) is a lncRNA, first found deregulated in bladder cancer, and many studies have exposed its oncogenic effects in more tumors since. However, the role of UCA1 in gynecological malignancies is still unclear. This review aims to analyze and define the role of UCA1 in GC, in order to identify its potential use as a diagnostic, prognostic, or therapeutic biomarker of GC...
March 21, 2024: Current Issues in Molecular Biology
https://read.qxmd.com/read/38534761/genetic-signatures-for-distinguishing-chemo-sensitive-from-chemo-resistant-responders-in-prostate-cancer-patients
#6
JOURNAL ARTICLE
Lemohang Gumenku, Mamello Sekhoacha, Beynon Abrahams, Samson Mashele, Aubrey Shoko, Ochuko L Erukainure
Prostate cancer remains a significant public health concern in sub-Saharan Africa, particularly impacting South Africa with high mortality rates. Despite many years of extensive research and significant financial expenditure, there has yet to be a definitive solution to prostate cancer. It is not just individuals who vary in their response to treatment, but even different nodules within the same tumor exhibit unique transcriptome patterns. These distinctions extend beyond mere differences in gene expression levels to encompass the control and networking of individual genes...
March 11, 2024: Current Issues in Molecular Biology
https://read.qxmd.com/read/38533040/comprehensive-single-cell-analysis-reveals-heterogeneity-of-fibroblast-subpopulations-in-ovarian-cancer-tissue-microenvironment
#7
JOURNAL ARTICLE
Bo Ding, Zheng Ye, Han Yin, Xin-Yi Hong, Song-Wei Feng, Jing-Yun Xu, Yang Shen
BACKGROUND: Ovarian cancer, as a highly malignant tumor, features the critical involvement of tumor-associated fibroblasts in the ovarian cancer tissue microenvironment. However, due to the apparent heterogeneity within fibroblast subpopulations, the specific functions of these subpopulations in the ovarian cancer tissue microenvironment remain insufficiently elucidated. METHODS: In this study, we integrated single-cell sequencing data from 32 ovarian cancer samples derived from four distinct cohorts and 3226 bulk RNA-seq data from GEO and TCGA-OV cohorts...
March 30, 2024: Heliyon
https://read.qxmd.com/read/38530846/a-phase-i-trial-of-nab-paclitaxel-bevacizumab-ab160-nano-immunoconjugate-therapy-for-gynecologic-malignancies
#8
JOURNAL ARTICLE
Eleftheria Kalogera, Wendy K Nevala, Heidi D Finnes, Vera J Suman, Jill M Schimke, Carrie A Strand, Lisa A Kottschade, Rachel A Kudgus, Sarah A Buhrow, Laura R Becher, Liyi Geng, Gretchen E Glaser, Megan E Grudem, Aminah Jatoi, Carolyn M Klampe, Amanika Kumar, Carrie L Langstraat, Robert R McWilliams, Andrea E Wahner Hendrickson, S John Weroha, Yiyi Yan, Joel M Reid, Svetomir N Markovic, Matthew S Block
PURPOSE: AB160 is a 160 nm nano-immunoconjugate consisting of nab-paclitaxel (ABX) nanoparticles non-covalently coated with bevacizumab (BEV) for targeted delivery into tissues expressing high levels of VEGF. Preclinical data showed that AB160 resulted in greater tumor targeting and tumor inhibition compared to sequential treatment with ABX then BEV. Given individual drug activity, we investigated the safety and toxicity of AB160 in patients with gynecologic cancers. PATIENTS AND METHODS: A 3+3 phase I trial was conducted with 3 potential dose levels in patients with previously treated endometrial (EC), cervical (CC), and platinum-resistant ovarian cancer (OC) patients to ascertain the recommended Phase II dose (RP2D)...
March 26, 2024: Clinical Cancer Research
https://read.qxmd.com/read/38518871/co-delivery-of-paclitaxel-atovaquone-quercetin-to-regulate-energy-metabolism-to-reverse-multidrug-resistance-in-ovarian-cancer-by-plga-peg-nanoparticles
#9
JOURNAL ARTICLE
Qingyu Lu, Wenhao Gao, Zhenzhen Chen, Zhihong Liu, Jie Wang, Lingjun Zeng, Xiaomu Hu, Enqin Zheng, Qian Zhang, Hongtao Song
Ovarian cancer is a malignant tumor that seriously endangers the lives of women, with chemotherapy being the primary clinical treatment. However, chemotherapy encounters the problem of generating multidrug resistance (MDR), mainly due to drug efflux induced by P-glycoprotein (P-gp), which decreases intracellular accumulation of chemotherapeutic drugs. The drugs efflux mediated by P-gp requires adenosine triphosphate (ATP) hydrolysis to provide energy. Therefore, modulating energy metabolism pathways and inhibiting ATP production may be a potential strategy to reverse MDR...
March 20, 2024: International Journal of Pharmaceutics
https://read.qxmd.com/read/38518726/a-novel-sik2-inhibitor-sic-19-exhibits-synthetic-lethality-with-parp-inhibitors-in-ovarian-cancer
#10
JOURNAL ARTICLE
Fang Wang, Xuejiao Yu, Jun Qian, Yumin Cao, Shunli Dong, Shenghua Zhan, Zhen Lu, Robert C Bast, Qingxia Song, Youguo Chen, Yi Zhang, Jinhua Zhou
PURPOSE: Ovarian cancer patients with HR proficiency (HRP) have had limited benefits from PARP inhibitor treatment, highlighting the need for improved therapeutic strategies. In this study, we developed a novel SIK2 inhibitor, SIC-19, and investigated its potential to enhance the sensitivity and expand the clinical utility of PARP inhibitors in ovarian cancer. METHODS: The SIK2 protein was modeled using a Molecular Operating Environment (MOE), and the most favorable model was selected based on a GBVI/WSA dG scoring function...
March 6, 2024: Drug Resistance Updates: Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy
https://read.qxmd.com/read/38518604/senolytic-drugs-dasatinib-and-quercetin-combined-with-carboplatin-or-olaparib-reduced-the-peritoneal-and-adipose-tissue-metastasis-of-ovarian-cancer
#11
JOURNAL ARTICLE
Lian Wang, Bing Xiong, Wei Lu, Yujie Cheng, Jihui Zhu, Guihai Ai, Xiaojie Zhang, Xiuni Liu, Zhongping Cheng
Chemotherapy and targeted drugs-induced senescent ovarian cancer cells that accumulate in peritoneal adipose tissue contribute significantly to chronic inflammation, disrupt homeostasis, and may fuel various aspects of cancer progression. However, the pro-senescence effects of chemotherapy and targeted drugs on adipose derived stem cells (ADSCs) within peritoneal adipose tissue remain poorly understood. In this study, we show that the first-line chemotherapy and targeted drugs can induce the cellular senescence of ADSCs in vitro and increase the aging of peritoneal adipose tissue in vivo...
March 21, 2024: Biomedicine & Pharmacotherapy
https://read.qxmd.com/read/38509422/organoids-in-ovarian-cancer-a-platform-for-disease-modeling-precision-medicine-and-drug-assessment
#12
REVIEW
Haiyao Hu, Chong'en Sun, Jingyao Chen, Zhengyu Li
Ovarian cancer (OC) is a major cause of gynecological cancer mortality, necessitating enhanced research. Organoids, cellular clusters grown in 3D model, have emerged as a disruptive paradigm, transcending the limitations inherent to conventional models by faithfully recapitulating key morphological, histological, and genetic attributes. This review undertakes a comprehensive exploration of the potential in organoids derived from murine, healthy population, and patient origins, encompassing a spectrum that spans foundational principles to pioneering applications...
March 20, 2024: Journal of Cancer Research and Clinical Oncology
https://read.qxmd.com/read/38500284/the-application-of-nanotechnological-therapeutic-platforms-against-gynecological-cancers
#13
JOURNAL ARTICLE
Vahideh Keyvani, Samaneh Mollazadeh, Espanta Riahi, Reihaneh Alsadat Mahmoudian, Masoomeh Tabari, Elmira Lagzian, Elnaz Ghorbani, Hamed Akbarzade, Amir-Sadra Gholami, Ibrahim Saeed Gataa, Seyed Mahdi Hassanian, Gordon A Ferns, Majid Khazaei, Amir Avan, Kazem Anvari
Gynecological cancers (GCs), ovarian, cervical, and endometrial/uterine cancers, are often associated with poor outcomes. Despite the development of several therapeutic modalities against GCs, the effectiveness of the current therapeutic approaches is limited due to their side effects, low therapeutic index, short halflife, and resistance to therapy. To overcome these limitations, nano delivery-based approaches have been introduced with the potential of targeted delivery, reduced toxicity, controlled release, and improved bioavailability of various cargos...
March 18, 2024: Current Pharmaceutical Design
https://read.qxmd.com/read/38492718/primpol-variant-v102a-with-altered-primase-and-polymerase-activities
#14
JOURNAL ARTICLE
O Boldinova Elizaveta, G Baranovskiy Andrey, V Filina Yulia, R Miftakhova Regina, F Shamsutdinova Yana, H Tahirov Tahir, Alena V Makarova
PrimPol is a human DNA primase-polymerase which restarts DNA synthesis beyond DNA lesions and non-B DNA structures blocking replication. Disfunction of PrimPol in cells leads to slowing of DNA replication rates in mitochondria and nucleus, accumulation of chromosome aberrations, cell cycle delay, and elevated sensitivity to DNA-damaging agents. A defective PrimPol has been suggested to be associated with the development of ophthalmic diseases, elevated mitochondrial toxicity of antiviral drugs and increased cell resistance to chemotherapy...
March 14, 2024: Journal of Molecular Biology
https://read.qxmd.com/read/38487220/tuning-the-photoactivated-anticancer-activity-of-pt-iv-compounds-via-distant-ferrocene-conjugation
#15
JOURNAL ARTICLE
Huayun Shi, Fortuna Ponte, Jaspreet S Grewal, Guy J Clarkson, Cinzia Imberti, Ian Hands-Portman, Robert Dallmann, Emilia Sicilia, Peter J Sadler
Photoactive prodrugs offer potential for spatially-selective antitumour activity with minimal effects on normal tissues. Excited-state chemistry can induce novel effects on biochemical pathways and combat resistance to conventional drugs. Photoactive metal complexes in particular, have a rich and relatively unexplored photochemistry, especially an ability to undergo facile intersystem crossing and populate triplet states. We have conjugated the photoactive octahedral Pt(iv) complex trans , trans , trans -[Pt(N3 )2 (OH)2 (py)2 ] to ferrocene to introduce novel features into a candidate photochemotherapeutic drug...
March 13, 2024: Chemical Science
https://read.qxmd.com/read/38486481/akting-on-r-loops-makes-for-an-atractive-target-in-ovarian-cancer-therapy
#16
JOURNAL ARTICLE
Vijayalalitha Ramanarayanan, Philipp Oberdoerffer
High-grade serous ovarian carcinoma (HGSOC) is the deadliest subtype of ovarian cancer. While PARP inhibitors (PARPi) have transformed the care of advanced HGSOC, PARPi resistance poses a major limitation to their clinical utility. DNA damage checkpoint signaling via ATR kinase can counteract PARPi-induced replication stress, making ATR an attractive therapeutic target in PARPi-resistant tumors. However, ATR inhibitor (ATRi) efficacy in the clinic is low, emphasizing the need for suitable combination treatments...
March 15, 2024: Cancer Research
https://read.qxmd.com/read/38474294/different-patterns-of-platinum-resistance-in-ovarian-cancer-cells-with-homologous-recombination-proficient-and-deficient-background
#17
JOURNAL ARTICLE
Michela Chiappa, Federica Guffanti, Chiara Grasselli, Nicolò Panini, Alessandro Corbelli, Fabio Fiordaliso, Giovanna Damia
Platinum compounds are very active in first-line treatments of ovarian carcinoma. In fact, high rates of complete remission are achieved, but most patients eventually relapse with resistant disease. Many mechanisms underlying the platinum-resistant phenotype have been reported. However, there are no data in the same isogenic cell system proficient and deficient in homologous recombination (HR) on platinum-acquired resistance that might unequivocally clarify the most important mechanism associated with resistance...
March 6, 2024: International Journal of Molecular Sciences
https://read.qxmd.com/read/38461424/investigating-the-mechanisms-of-drug-resistance-and-prognosis-in-ovarian-cancer-using-single-cell-rna-sequencing-and-bulk-rna-sequencing
#18
JOURNAL ARTICLE
Pengfei Liu, Jinbao Liu, Jinxing Liu, Xiao Yu
Ovarian cancer stands as a prevalent malignancy within the realm of gynecology, and the emergence of resistance to chemotherapeutic agents remains a pivotal impediment to both prognosis and treatment. Through a single-cell level investigation, we scrutinize the drug resistance and mitotic activity of the core tumor cells in ovarian cancer. Our study revisits the interrelationships and temporal trajectories of distinct epithelial cells (EPCs) subpopulations, while identifying genes associated with ovarian cancer prognosis...
March 8, 2024: Aging
https://read.qxmd.com/read/38461218/static-magnetic-field-reduces-cisplatin-resistance-via-increasing-apoptosis-pathways-and-genotoxicity-in-cancer-cell-lines
#19
JOURNAL ARTICLE
Jaber Zafari, Nima Rastegar-Pouyani, Fatemeh Javani Jouni, Nabaa Najjar, Seyedeh Zohreh Azarshin, Emad Jafarzadeh, Parviz Abdolmaleki, Farshad Hoseini Shirazi
Cisplatin is a chemotherapy drug widely used in cancer treatment. Alongside its clinical benefits, however, it may inflict intolerable toxicity and other adverse effects on healthy tissues. Due to the limitation of administering a high dose of cisplatin as well as cancer drug resistance, it is necessary to utilize new methods optimizing treatment modalities through both higher therapeutic efficacy and reduced administered doses of radiation and drugs. In this study, sensitive (A2780) and resistant (A2780CP) ovarian carcinoma cells underwent treatment with cisplatin + static magnetic field (SMF)...
March 9, 2024: Scientific Reports
https://read.qxmd.com/read/38455223/therapeutic-potential-of-mangiferin-in-cancer-unveiling-regulatory-pathways-mechanisms-of-action-and-bioavailability-enhancements-an-updated-review
#20
REVIEW
Humaira Iqbal, Muhammad Inam-Ur-Raheem, Seemal Munir, Roshina Rabail, Sadia Kafeel, Arashi Shahid, Amin Mousavi Khaneghah, Rana Muhammad Aadil
Mangiferin (MGF) is a phenolic compound, which is a major source of MGF is the mango tree. MGF possesses some antioxidant, anti-inflammatory, and cytoprotective properties, enabling it to play its role against various diseases such as diabetes, obesity, lung injuries, and cancer. The word "Cancer" depicts an uncontrolled and abnormal growth of cells. This review paper reveals MGF's therapeutic, curative and protective potential impact against lung, liver, ovarian, prostate, breast, stomach, and oral cancers...
March 2024: Food Science & Nutrition
keyword
keyword
164841
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.